Αποτελέσματα Αναζήτησης
Observational and Clinical Outcomes Researcher, Effective Team Leader · Accomplished Research Director with significant experience in Pharmaceutical and Healthcare clinical research, with over 70...
Lincy LAL | Cited by 1,157 | of University of Texas Health Science Center at Houston, Texas | Read 165 publications | Contact Lincy LAL
Eltrombopag is a well-studied treatment for primary ITP, but evidence is scarce for sITP. We evaluated real-world use of eltrombopag for sITP using electronic health records. Eligible patients had diagnoses of ITP and a qualifying predisposing condition, and eltrombopag treatment.
11 Σεπ 2020 · Second-line treatment for immune thrombocytopenia (ITP) is not well reported for patients treated in real-world clinical settings. The purpose of this study was to compare outcomes of four second-line treatments for ITP.
16 Μαρ 2018 · Lincy Subha Lal, PharmD, PhD, is a research specialist in drug use policy at UT MD Anderson Cancer Center, Houston, Texas.
Lincy S. Lal, PhD, PharmD Director, Therapeutic Lead, Oncology Dr. Lincy Lal joined Optum in 2016. As therapeutic lead of oncology, Dr. Lal provides oversight of opportunities and studies in this area, including development of opportunities and coordination of clinical and scientific input. Dr. Lal has particular experience in
For patients with rheumatoid arthritis (RA) who have not responded to their first tumor necrosis factor inhibitor (TNFi), there are 2 basic approaches to treatment: cycling (switching to another TNFi) or switching to a drug with another mechanism of action.
